Trump's Deregulatory Agenda: What It Could Mean For Biopharma & Medtech Companies
Pharmaceutical Online- What do President Trump’s deregulatory executive orders mean for the industry? In this article in Pharmaceutical Online, Catalyst’s Nancy Bradish Myers and Anne Petruska McNickle explore Trump’s “2-for-1” and Task Force executive orders and the accompanying guidance from the Office of Management and Budget’s (OMB), and offer their